21 May 2022
31 May 2022
Chronic kidney disease (CKD) is generally a progressive condition that is characterized by significant changes in the structure and function of the kidney as a result of different causes. Chemerin, a novel chemokine and adipokine, is principally produced in adipocytes and liver. It is mainly involved in lipid and carbohydrates metabolism. The present paper aims to evaluate chemerin levels in Iraqi CKD subjects, and to compare serum concentrations of chemerin in CKD subjects with and without diabetes mellitus. Thus, sixty CKD patients compared with thirty normal control group were investigated. The age of the subjects ranged from 30-55 years. The CKD patients have been also subdivided into 2 groups: thirty CKD patients with T2D and thirty CKD patients without T2D. Blood samples have been collected and analyzed for fasting blood glucose, postprandial blood glucose, hemoglobin A1c, urea, creatinine, high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol. The estimation of serum fasting insulin and chemerin levels have been made by ELISA kits. Moreover, calculations of the HOMA-IR, and eGFR have been made. Serum levels of chemerin were highly significantly elevated in CKD patients compared with normal controls. Moreover, serum chemerin concentrations were highly significantly elevated in the CKD group with diabetes compared with CKD group without diabetes. These results would seem to suggest that serum concentrations of chemerin are likely to become a possible marker for assessment of T2D in CKD patients.